The clinical heterogeneity of more than 80 autoimmune diseases presents a significant challenge with respect to the development of therapies designed to re-establish self-tolerance. As the first generation of antigen-specific immune tolerance therapies enters the clinic and excitement around the recent deals, partnerships, IPOs and investments reaching new heights, now is the time for an industry forum for large pharma, pioneering biotech and academia to unite.
Tackling key R&D challenges, such as antigen and, animal model predictability, translation and clinical design, the Antigen-Specific Immune Tolerance Europe Summit is the first European centric, dedicated platform that brings key decision makers together to successfully translate ground breaking science into a novel class of therapies to treat autoimmunity.
+44 (0)20 3141 8700
Conference + 2 Workshops Earlybird (Book by 07/09/18): GBP 2297.0,
Conference + 2 Workshops (standard rate): GBP 2897.0,
Conference + 1 Workshop Earlybird (Book by 07/09/18): GBP 1898.0,
Conference + 1 Workshop (standard rate): GBP 2498.0,
Conference Only Earlybird (Book by 07/09/18): GBP 1399.0,
Conference (Standard rate): GBP 1999.0,
Workshop: GBP 499.0
Speakers: Robert (Bob) Anderson (ImmusanT), Arpita Maiti (Pfizer), Keith Martin (Apitope), Tim Jessen (Topas Therapeutics), Lawrence Steinman (Tolerion), David Wraith (University of Birmingham), Tim Schmidt (TxCell), José Carballido (Novartis), Mark Peakman (King's College London)